MEDICAMEQ

** Shares of Medicamen Biotech MEBI.NS rise 4% to 434.95 rupees

** Drugmaker gets U.S. FDA approval for Bortezomib injection 3.5 mg

** Bortezomib therapeutically equivalent to Takeda's 4502.T blood cancer drug Velcade

** More than 49,576 shares traded, 2.1x 30-day moving avg

** Stock trims YTD losses to ~3%

(Reporting by Rudra Pratap Singh in Bengaluru)

(([email protected]))

April 24 (Reuters) - Medicamen Biotech Ltd MEBI.NS:

• APPROVED ALLOTMENT OF 848,220 SHARES AT 530 RUPEES EACH

• ALLOTMENT OF 650,000 WARRANTS AT 530 RUPEES EACH

Source text: ID:nNSE5MTZSF

Further company coverage: MEBI.NS

(([email protected];;))

** Medicamen Biotech MEBI.NS soars as much as 11.5% amid a broader market rebound; stock had dropped 8.4% on Monday, tracking a sell-off triggered by U.S. tariffs

** Gains helped by co's agreement with Denmark's XGX Pharma to distribute three products in Europe

** Co will hold marketing authorization of products

** More than 84,000 shares traded vs 30-day avg of 67,923

** MEBI last up 8.7%, cutting YTD losses to 10.6%

(Reporting by Meenakshi Maidas in Bengaluru)

(([email protected];))

March 28 (Reuters) - Medicamen Biotech Ltd MEBI.NS:

• MEDICAMEN BIOTECH LTD - ANNOUNCES STRATEGIC EXPANSION INTO REGULATED MARKETS

• MEDICAMEN BIOTECH LTD - OBTAINS EU AND USFDA APPROVALS FOR MANUFACTURING PLANTS

Source text: ID:nNSE4R5B73

Further company coverage: MEBI.NS

(([email protected];;))

March 7 (Reuters) - Medicamen Biotech Ltd MEBI.NS:

• ENTERS AGREEMENT WITH SOUTH AFRICAN CONGLOMERATE

Source text: ID:nNSE4dSgXC

Further company coverage: MEBI.NS

(([email protected];;))

Feb 26 (Reuters) - Medicamen Biotech Ltd MEBI.NS:

• MEDICAMEN BIOTECH LTD - PREFERENTIAL ISSUE OF SHARES WORTH UPTO 689 MILLION RUPEES

Source text: ID:nBSE68zb7g

Further company coverage: MEBI.NS

(([email protected];;))

** Medicamen Biotech MEBI.NS rises as much as 5.3% to 523 rupees

** Co signs 10-year contract manufacturing deal with a US-based pharma distributor and marketing firm; financials not disclosed but 25% payment due upfront

** Over 12,000 shares traded as of 9:46 a.m. IST, over half of their 30-day moving avg

** Stock last up 4.7%, cutting YTD losses to 3.1%

(Reporting by Meenakshi Maidas in Bengaluru)

(([email protected];))

Feb 19 (Reuters) - Medicamen Biotech Ltd MEBI.NS:

• MEDICAMEN BIOTECH - ENTERS MANUFACTURING & SUPPLY AGREEMENT WITH US, EUROPE PHARMA DISTRIBUTOR

• MEDICAMEN BIOTECH LTD - 25% AMOUNT PAID ON SIGNING OF AGREEMENT OF 10 YRS

Source text: ID:nBSE35TP8k

Further company coverage: MEBI.NS

(([email protected];;))

Oct 25 (Reuters) - Medicamen Biotech Ltd MEBI.NS:

• US FDA APPROVED STERILE INJECTABLE ONCOLOGY FORMULATION FACILITY AT HARIDWAR

Source text for Eikon: ID:nBSE9QTBJ4

Further company coverage: MEBI.NS

(([email protected];;))

** Shares of Medicamen Biotech MEBI.NS rise 9.3% to 484 rupees, on track for best day since July 3

** Pharma co's facility in Indian state of Rajasthan got EU GMP certification from National Organisation for Medicines, Greece

** Stock on track to rise in fourth straight session, gained 16% in this time

** Stock down ~20% YTD after falling for two straight years

(Reporting by Varun Vyas in Bengaluru)

(([email protected]))

Sept 11 (Reuters) - Medicamen Biotech Ltd MEBI.NS:

• MEDICAMEN BIOTECH - GETS EU GMP CERTIFICATION FOR BHIWADI FORMULATION FACILITY

Source text for Eikon: ID:nBSE57SDXR

Further company coverage: MEBI.NS

(([email protected];))

March 26 (Reuters) - Medicamen Biotech Ltd MEBI.NS:

• ETHIOPIAN FDA HAS CONDUCTED AUDIT OF ONCOLOGY PLANT, HARIDWAR

• AWAITING PLANT APPROVAL FROM FDA

Source text for Eikon: ID:nBSE4STCHT

Further company coverage: MEBI.NS

(([email protected];))

July 19 (Reuters) - Medicamen Biotech Ltd MEBI.NS:

• HAS FILED FIRST ANDA IN ECTD FORMAT FOR BORTEZOMIB FOR INJECTION 3.5 MG/VIAL WITH USFDA

Source text for Eikon: ID:nBSE2CwQ8R

Further company coverage: MEBI.NS

(([email protected];;))

May 29 (Reuters) - Medicamen Biotech Ltd MEBI.NS:

• FINAL DIVIDEND 1 RUPEE PER SHARE

Source text for Eikon: ID:nBSErl9BD

Further company coverage: MEBI.NS

(([email protected];))